S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
As Musk is learning, content moderation is a messy job
Intel is a Sleeping Giant Ready to Awaken
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
Reformers take 6 of 14 UAW board seats, could win majority
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
As Musk is learning, content moderation is a messy job
Intel is a Sleeping Giant Ready to Awaken
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
Reformers take 6 of 14 UAW board seats, could win majority
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
As Musk is learning, content moderation is a messy job
Intel is a Sleeping Giant Ready to Awaken
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
Reformers take 6 of 14 UAW board seats, could win majority
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
As Musk is learning, content moderation is a messy job
Intel is a Sleeping Giant Ready to Awaken
Tiny $4 Company to “Steal” Billions From Tesla?  (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
Reformers take 6 of 14 UAW board seats, could win majority
NYSE:PEN

Penumbra - PEN Stock Forecast, Price & News

$210.85
+0.74 (+0.35%)
(As of 12/2/2022 09:00 PM ET)
Add
Compare
Today's Range
$206.11
$212.19
50-Day Range
$151.88
$210.85
52-Week Range
$114.86
$290.36
Volume
259,100 shs
Average Volume
318,948 shs
Market Capitalization
$8.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$220.45

Penumbra MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
4.6% Upside
$220.45 Price Target
Short Interest
Bearish
8.53% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.75
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$1.62 M Sold Last Quarter
Proj. Earnings Growth
564.29%
From $0.14 to $0.93 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

481st out of 1,033 stocks

Surgical & Medical Instruments Industry

50th out of 104 stocks

PEN stock logo

About Penumbra (NYSE:PEN) Stock

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

PEN Stock News Headlines

Penumbra (PEN) Tops Q3 Earnings and Revenue Estimates
Citigroup Downgrades Penumbra to Neutral
7 Analysts Have This to Say About Penumbra
Analyst Ratings for Penumbra
See More Headlines
Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

PEN Company Calendar

Last Earnings
11/03/2022
Today
12/05/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/28/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Employees
3,800
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$220.45
High Stock Price Forecast
$300.00
Low Stock Price Forecast
$185.00
Forecasted Upside/Downside
+4.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
12 Analysts

Profitability

Net Income
$5.28 million
Pretax Margin
-5.32%

Debt

Sales & Book Value

Annual Sales
$747.59 million
Cash Flow
$1.14 per share
Book Value
$25.53 per share

Miscellaneous

Free Float
35,890,000
Market Cap
$8.01 billion
Optionable
Optionable
Beta
0.51

Key Executives

  • Mr. Adam ElsesserMr. Adam Elsesser (Age 60)
    Co-Founder, Chairman, Pres & CEO
    Comp: $497.79k
  • Dr. Arani Bose M.D. (Age 60)
    Co-Founder & Director
  • Ms. Maggie S. Yuen (Age 50)
    Chief Financial Officer
    Comp: $616.3k
  • Mr. Lambert Shiu (Age 42)
    Chief Accounting Officer
    Comp: $468.76k
  • Ms. Johanna RobertsMs. Johanna Roberts (Age 50)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $608.84k
  • Ms. Lynn Rothman (Age 61)
    Exec. VP & Chief Bus. Officer
    Comp: $605.5k
  • Mr. Ben Sorci
    Exec. VP of Operations
  • Mr. Pankaj Tiwari
    Exec. VP & Chief Information Officer
  • Ms. Jee Hamlyn-Harris
    Investor Relations Officer
  • Ms. Shruthi Narayan
    Director of Marketing - Vascular













PEN Stock - Frequently Asked Questions

Should I buy or sell Penumbra stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last twelve months. There are currently 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PEN shares.
View PEN analyst ratings
or view top-rated stocks.

What is Penumbra's stock price forecast for 2023?

12 equities research analysts have issued 12-month price targets for Penumbra's shares. Their PEN share price forecasts range from $185.00 to $300.00. On average, they predict the company's share price to reach $220.45 in the next year. This suggests a possible upside of 4.6% from the stock's current price.
View analysts price targets for PEN
or view top-rated stocks among Wall Street analysts.

How have PEN shares performed in 2022?

Penumbra's stock was trading at $287.32 at the beginning of the year. Since then, PEN shares have decreased by 26.6% and is now trading at $210.85.
View the best growth stocks for 2022 here
.

Are investors shorting Penumbra?

Penumbra saw a increase in short interest in the month of October. As of October 31st, there was short interest totaling 2,800,000 shares, an increase of 18.1% from the October 15th total of 2,370,000 shares. Based on an average daily trading volume, of 353,200 shares, the days-to-cover ratio is currently 7.9 days. Currently, 7.7% of the company's shares are short sold.
View Penumbra's Short Interest
.

When is Penumbra's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 28th 2023.
View our PEN earnings forecast
.

How were Penumbra's earnings last quarter?

Penumbra, Inc. (NYSE:PEN) announced its earnings results on Thursday, November, 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.01) by $0.02. The firm earned $213.68 million during the quarter, compared to the consensus estimate of $212.41 million. Penumbra had a positive trailing twelve-month return on equity of 0.45% and a negative net margin of 3.68%.

What guidance has Penumbra issued on next quarter's earnings?

Penumbra updated its FY 2022 earnings guidance on Thursday, November, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $840.00 million-$845.00 million, compared to the consensus revenue estimate of $860.97 million.

What is Adam Elsesser's approval rating as Penumbra's CEO?

57 employees have rated Penumbra Chief Executive Officer Adam Elsesser on Glassdoor.com. Adam Elsesser has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Penumbra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Netflix (NFLX), UnitedHealth Group (UNH), Boeing (BA) and DexCom (DXCM).

What is Penumbra's stock symbol?

Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."

Who are Penumbra's major shareholders?

Penumbra's stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.28%), Vanguard Group Inc. (8.97%), Baillie Gifford & Co. (3.33%), Price T Rowe Associates Inc. MD (2.71%), State Street Corp (2.68%) and Bank of New York Mellon Corp (0.94%). Insiders that own company stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Sridhar Kosaraju, Surbhi Sarna and Thomas Wilder.
View institutional ownership trends
.

How do I buy shares of Penumbra?

Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Penumbra's stock price today?

One share of PEN stock can currently be purchased for approximately $210.85.

How much money does Penumbra make?

Penumbra (NYSE:PEN) has a market capitalization of $8.01 billion and generates $747.59 million in revenue each year. The company earns $5.28 million in net income (profit) each year or ($0.82) on an earnings per share basis.

How many employees does Penumbra have?

The company employs 3,800 workers across the globe.

How can I contact Penumbra?

Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The official website for the company is www.penumbrainc.com. The company can be reached via phone at (510) 748-3200, via email at investors@penumbrainc.com, or via fax at 510-748-3232.

This page (NYSE:PEN) was last updated on 12/5/2022 by MarketBeat.com Staff